메뉴 건너뛰기




Volumn 11, Issue 1, 2014, Pages

Therapeutic drug monitoring of voriconazole: A case report of multiple drug interactions in a patient with an increased CYP2C19 activity

Author keywords

antifungal; CYP; Drug interaction; Individualization; Pharmacogenetics; Therapeutic drug monitoring

Indexed keywords

AMPHOTERICIN B; ATAZANAVIR; CYTOCHROME P450 2C19; DEXAMETHASONE; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ESOMEPRAZOLE; FLUCYTOSINE; OMEPRAZOLE; RALTEGRAVIR; RANITIDINE; TENOFOVIR; VORICONAZOLE;

EID: 84905821220     PISSN: None     EISSN: 17426405     Source Type: Journal    
DOI: 10.1186/1742-6405-11-25     Document Type: Article
Times cited : (13)

References (14)
  • 4
    • 84859085055 scopus 로고    scopus 로고
    • Drug interactions between voriconazole, darunavir/ritonavir and etravirine in an HIV-infected patient with Aspergillus pneumonia
    • Aouri M, Decosterd LA, Buclin T, Hirschel B, Calmy A, Livio F. Drug interactions between voriconazole, darunavir/ritonavir and etravirine in an HIV-infected patient with Aspergillus pneumonia. AIDS 2012, 26(6):776-778.
    • (2012) AIDS , vol.26 , Issue.6 , pp. 776-778
    • Aouri, M.1    Decosterd, L.A.2    Buclin, T.3    Hirschel, B.4    Calmy, A.5    Livio, F.6
  • 5
    • 79959400397 scopus 로고    scopus 로고
    • Pharmacogenomics of the triazole antifungal agent voriconazole
    • Mikus G, Scholz IM, Weiss J. Pharmacogenomics of the triazole antifungal agent voriconazole. Pharmacogenomics 2011, 12(6):861-872.
    • (2011) Pharmacogenomics , vol.12 , Issue.6 , pp. 861-872
    • Mikus, G.1    Scholz, I.M.2    Weiss, J.3
  • 6
    • 84869029614 scopus 로고    scopus 로고
    • Effect of CYP2C19 Polymorphism on the Pharmacokinetics of Voriconazole After Single and Multiple Doses in Healthy Volunteers
    • Lee S, Kim BH, Nam WS, Yoon SH, Cho JY, Shin SG, Jang IJ, Yu KS. Effect of CYP2C19 Polymorphism on the Pharmacokinetics of Voriconazole After Single and Multiple Doses in Healthy Volunteers. J Clin Pharmacol 2011,
    • (2011) J Clin Pharmacol
    • Lee, S.1    Kim, B.H.2    Nam, W.S.3    Yoon, S.H.4    Cho, J.Y.5    Shin, S.G.6    Jang, I.J.7    Yu, K.S.8
  • 7
    • 78650070154 scopus 로고    scopus 로고
    • Clinical importance of the CYP2C19*17 variant allele for voriconazole
    • Dolton MJ, McLachlan AJ. Clinical importance of the CYP2C19*17 variant allele for voriconazole. Br J Clin Pharmacol 2011, 71(1):137-138.
    • (2011) Br J Clin Pharmacol , vol.71 , Issue.1 , pp. 137-138
    • Dolton, M.J.1    McLachlan, A.J.2
  • 11
    • 84868014757 scopus 로고    scopus 로고
    • Utilization of omeprazole to augment subtherapeutic voriconazole concentrations for treatment of Aspergillus infections
    • Boyd NK, Zoellner CL, Swancutt MA, Bhavan KP. Utilization of omeprazole to augment subtherapeutic voriconazole concentrations for treatment of Aspergillus infections. Antimicrob Agents Chemother 2012, 56(11):6001-6002.
    • (2012) Antimicrob Agents Chemother , vol.56 , Issue.11 , pp. 6001-6002
    • Boyd, N.K.1    Zoellner, C.L.2    Swancutt, M.A.3    Bhavan, K.P.4
  • 12
    • 0344512407 scopus 로고    scopus 로고
    • Histamine H2-receptor antagonists have no clinically significant effect on the steady-state pharmacokinetics of voriconazole
    • Purkins L, Wood N, Kleinermans D, Nichols D. Histamine H2-receptor antagonists have no clinically significant effect on the steady-state pharmacokinetics of voriconazole. Br J Clin Pharmacol 2003, 56(Suppl 1):51-55.
    • (2003) Br J Clin Pharmacol , vol.56 , pp. 51-55
    • Purkins, L.1    Wood, N.2    Kleinermans, D.3    Nichols, D.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.